Health & Biotech

Best MedTech Startups to Watch: How Sequenex Is Speeding Connected Device Development

Wednesday, 6 May 2026 6:31AM UTC

Shoppers of innovation, take note , Sequenex has teamed up with MedTech Innovator to give early-stage medtech companies the software muscle they need, helping wearable, CGM and biosensor startups move faster to market and improve patient outcomes. This partnership matters because it cuts friction around regulatory-ready, connected device development.

Essential Takeaways

New partnership: Sequenex is a sponsor and hands-on partner with MedTech Innovator to support early- and growth-stage medtech firms.
Software boost: Sequenex offers its prebuilt, customisable NEX platform for compliant connected-device software, helpful for CGM, wearables and biosensors.
Scale and speed: The collaboration aims to shorten development timelines and streamline regulatory readiness, making products market-ready sooner.
Programme reach: MedTech Innovator will select 65 startups for its 2026 accelerator after a competitive application process that drew record interest.
Visible milestones: The accelerator runs through panels, a June Innovator Summit in San Francisco and culminates with finals in October, where companies pitch to partners and investors.

Why this partnership feels important now

This deal reads like a practical hand-up rather than just another sponsorship. Sequenex brings a tangible toolset , a compliant, scalable software platform , which smells faintly of relief for hardware-first startups that suddenly hit software and regulatory walls. MedTech Innovator has long been the place where investors and mentors meet early-stage companies, and adding a software partner with deep regulated-experience plugs a real gap.

MedTech Innovator is the largest accelerator focused on medical technology, and its 2026 cohort will include 65 companies selected from a deep pool. For a founder, having software that’s already engineered to be regulatory-ready can be the difference between another year spent on integration and a product that’s actually useful to patients.

What Sequenex is actually offering founders

Sequenex’s NEX platform is pitched as prebuilt and customisable, which means startups don’t need to reinvent the wheel for connectivity, data handling, or regulatory compliance. That’s especially valuable for continuous glucose monitoring (CGM) devices, biosensors and consumer wearables where data integrity and patient safety are non-negotiable.

According to Sequenex’s own service descriptions, they provide compliant software development and integration services , essentially taking on the heavy lifting startups dread. In practice, founders can expect faster prototyping, clearer regulatory pathways and a sturdier feel to their software stack.

How MedTech Innovator’s accelerator amplifies impact

MedTech Innovator runs a structured pathway: review, Radar Forum pitches, cohort selection, an invite-only Innovator Summit and a final competition in October. The accelerator connects startups to mentors, industry partners and investors, so the Sequenex offer slots into each stage , from early product validation to investment-ready demos.

The programme is highly competitive; recent rounds saw record applications, so being selected brings credibility as well as resources. For investors and hospital partners watching the MTI funnel, a startup backed by a partner providing regulatory-ready software looks less risky and more partnerable.

What founders should consider before signing up

This is great news, but founders should be pragmatic. Ask how much custom code you’ll still need, who owns the IP for integrations, and how the NEX platform handles data security and post-market software updates. Check timelines: the faster you can map your product to a platform, the more value you’ll extract from MTI mentorship and demo opportunities.

If you’re applying, get your regulatory story straight before you pitch , MTI reviewers want to see a concrete plan for safety and compliance. And remember, partnerships like this are about leverage: the platform speeds things up, but clinical validation, manufacturing and distribution still take focus and capital.

What this means for patients and the wider market

When startups move faster and more safely, patients win: better devices reach clinics sooner and can improve monitoring and outcomes. Industry-wide, this kind of partnership nudges the market toward integrated hardware-software ecosystems, where interoperability and secure connectivity are assumed rather than bolted on.

So expect to see more polished, connected devices emerging from accelerators in the coming year, and a clearer path from prototype to prescription-level reliability.

It's a small change that can make every connected device launch smoother and, ultimately, more useful to patients.

Source Reference Map

Story idea inspired by: ^[1]

Sources by paragraph:

Paragraph 1: ^[2], ^[4]
Paragraph 2: ^[3], ^[5]
Paragraph 3: ^[4], ^[2]
Paragraph 4: ^[3], ^[5]
Paragraph 5: ^[6], ^[2]
Paragraph 6: ^[4], ^[3]

More on this

https://www.todaysmedicaldevelopments.com/news/sequenex-joins-medtech-innovator-support-emerging-medical-technology-companies/ - Please view link - unable to able to access data
https://www.todaysmedicaldevelopments.com/news/sequenex-joins-medtech-innovator-support-emerging-medical-technology-companies/ - Sequenex has partnered with MedTech Innovator (MTI), the world's largest accelerator for medical technology companies. MTI connects healthcare industry leaders with innovative early-stage medtech companies for mentorship and support. In 2026, MTI plans to select 65 startups for its program. Sequenex will collaborate directly with emerging companies and provide financial support to MTI. The partnership aims to assist early- and growth-stage medtech companies by offering scalable, regulatory-ready software solutions for connected medical devices, including continuous glucose monitors (CGMs), biosensors, and wearables. Sequenex's expertise in compliant software development and its customizable NEX platform are expected to accelerate development timelines and streamline regulatory readiness, facilitating the efficient market introduction of transformative medical technologies. John Krlin, CTO of Sequenex, stated that the partnership aligns with their mission to eliminate barriers to innovation in connected medical devices. Paul Grand, founder and CEO of MTI, expressed pride in their success in discovering and supporting promising medical technology and digital health companies, welcoming Sequenex as a new partner to improve patient outcomes and create lasting value across the healthcare ecosystem. As a partner, Sequenex will engage with MTI at critical points throughout the year. MTI received a record 1,800 applications for this year's program, with the top 10% advancing to the Radar Forum held from April 7 to 9 in Manhattan Beach and virtually, providing an opportunity to pitch and engage with the MTI ecosystem. The 2026 accelerator will officially launch at the Innovator Summit on June 3 to 4 in San Francisco, where companies from the latest cohorts will convene with representatives from MTI’s partners, mentors, and alumni. The program will culminate in October at the Finals Competitions, where partners will reconnect with the cohort as companies showcase their progress and readiness for partnership and investment.
https://medtechinnovator.org/about-us/ - MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Its mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. The organisation offers various programmes, including the US, APAC, and BioTools programmes, each with its own cohort and several rounds where companies gain exposure to industry leaders through online application reviews, pitch events, and audience competitions at major industry conferences. The MedTech Innovator Radar Forum is a key component of the evaluation process, where approximately 10% of over 1,800 applicants are advanced to pitch at the forum in April or at a virtual pitch event. During this high-value engagement and diligence forum, presenters receive feedback from up to 250 judges, including investors, clinicians, and senior executives from leading industry partners such as Johnson & Johnson, Olympus, Edwards Life Sciences, LivaNova, Samsung Research America, Asahi Intecc, Zimmer Biomet, and Dexcom. The MedTech Innovator Accelerator selects over 50 of the most innovative companies from around the world to participate in a four-month virtual programme from June to October. Companies receive coaching and high-profile visibility at the Wilson Sonsini Medical Device Conference in June and The MedTech Innovator Showcase programme at The MedTech Conference, powered by AdvaMed, in October. Early-stage companies (pre-Series B) are assigned mentors from one or more of MedTech Innovator’s corporate partners and compete for up to $500,000 in funding. The programme concludes with all cohort companies participating in the Accel Leadership Seminar, the MedTech Innovator Showcase, and an opportunity to compete to present in the finals at The MedTech Conference or the Mid-Stage competition at MedTech Strategist in November.
https://sequenex.com/our-services/ - Sequenex is a full-service medtech software development partner specialising in Software as a Medical Device (SaMD) solutions and products for connected devices, continuous glucose monitoring (CGM) systems, and biosensors. The company offers services ranging from proof of concept and clinical software development to minimum viable product (MVP) and commercial software product initiatives. Sequenex's prebuilt and configurable NEX Platform is designed to accelerate the delivery of mobile, cloud, and device-integrated applications, saving more than 80% in time and development costs. The platform is regulatory-ready and compliant by design for MedTech, complete with iOS and Android companion apps, patient and clinician dashboards, an administrator portal, and secure cloud infrastructure. Operating under an ISO 13485–certified Quality Management System, Sequenex develops medtech software in accordance with IEC 62304 and ISO 14971 standards, supporting the full product lifecycle from prototype to clinical and commercial systems. The company's approach combines a reusable software foundation with custom development to enable rapid device integration while maintaining a clear path to regulatory submission.
https://medtechinnovator.org/apply/ - MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies, aiming to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. The organisation's accelerator programme is remote-friendly and has been operating as a virtual programme since 2015. Each year, MedTech Innovator recognises over 50 best-in-class startups and scale-ups across the medtech industry. All companies invited to pitch receive PDF feedback summaries from judges. The accelerator programme offers companies access to corporate executives, investors, providers, payers, FDA, NIH, DoD, and other stakeholders, and they join an exclusive peer alumni network of over 500 of the highest performing medtech startups globally. All accelerator companies receive one complimentary registration to the WSGR Medical Device Conference in San Francisco in June, as well as one full-access registration to The MedTech Conference, powered by AdvaMed in October. At both conferences, companies participate in the MedTech Innovator Showcase, an on-stage interactive programme. Early-stage companies (pre-Series B) are assigned mentors from one or more of MedTech Innovator’s corporate partners and compete for up to $500,000 in funding. The programme concludes with all cohort companies participating in the Accel Leadership Seminar, the MedTech Innovator Showcase, and an opportunity to compete to present in the finals at The MedTech Conference or the Mid-Stage competition at MedTech Strategist in November.
https://medtechinnovator.org/mti-aha-track/ - The Heart and Brain Health Accelerator, powered by MedTech Innovator, is led by the American Heart Association in collaboration with the Association’s Center for Health Technology and Innovation. This track is designed to identify and support startups with novel medical technologies focused on heart and brain health, including prevention, diagnosis, treatment, and secondary prevention. It is open to companies at the Seed, Series A, and Series B stages. The 2026 track focuses on two areas: 1) Women’s Cardiovascular and Brain Health: Startups addressing issues unique to, disproportionately affecting, or differentially impacting women. Applications for the 2026 Accelerator are open, and interested companies should indicate their interest in this specialty track on the application.

Noah Fact Check Pro

The draft above was created using the information available at the time the story first emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed below. The results are intended to help you assess the credibility of the piece and highlight any areas that may warrant further investigation.

Freshness check

Score: 8

Notes: The partnership announcement was published on May 1, 2026, with the earliest known publication date being May 1, 2026. ([biospace.com](https://www.biospace.com/press-releases/sequenex-announces-partnership-with-medtech-innovator-industrys-leading-startup-accelerator?utm_source=openai)) The content has been republished across various reputable sources, including BioSpace and Weekly Voice. ([biospace.com](https://www.biospace.com/press-releases/sequenex-announces-partnership-with-medtech-innovator-industrys-leading-startup-accelerator?utm_source=openai)) No significant discrepancies in figures, dates, or quotes were found. The narrative appears original and fresh.

Quotes check

Score: 7

Notes: Direct quotes from John Krlin, CTO of Sequenex, and Paul Grand, CEO of MedTech Innovator, are included. ([biospace.com](https://www.biospace.com/press-releases/sequenex-announces-partnership-with-medtech-innovator-industrys-leading-startup-accelerator?utm_source=openai)) These quotes are consistent across multiple reputable sources. However, the absence of independent verification of these quotes raises some concern. ([biospace.com](https://www.biospace.com/press-releases/sequenex-announces-partnership-with-medtech-innovator-industrys-leading-startup-accelerator?utm_source=openai))

Source reliability

Score: 8

Notes: The lead source, BioSpace, is a reputable platform for life sciences news. ([biospace.com](https://www.biospace.com/press-releases/sequenex-announces-partnership-with-medtech-innovator-industrys-leading-startup-accelerator?utm_source=openai)) The content has been republished across other reputable sources, including Weekly Voice. ([weeklyvoice.com](https://weeklyvoice.com/sequenex-announces-partnership-with-medtech-innovator-industrys-leading-startup-accelerator/?utm_source=openai)) No evidence suggests the content is recycled from low-quality sites or clickbait networks. The narrative appears to originate from a press release, which typically warrants a high freshness score.

Plausibility check

Score: 8

Notes: The claims about the partnership between Sequenex and MedTech Innovator are plausible and align with industry trends. The narrative lacks specific factual anchors, such as detailed figures or dates, which could enhance credibility. The language and tone are consistent with typical corporate communications. No excessive or off-topic details are present. The tone is professional and appropriate for the subject matter.

Overall assessment

Verdict (FAIL, OPEN, PASS): FAIL

Confidence (LOW, MEDIUM, HIGH): MEDIUM

Summary: While the partnership announcement between Sequenex and MedTech Innovator is plausible and aligns with industry trends, the lack of independent verification sources and the reliance on press releases and promotional content from the companies involved raise concerns about the reliability of the information. The absence of independent verification of direct quotes further diminishes confidence in the narrative's accuracy. Therefore, the overall assessment is a FAIL with MEDIUM confidence.